Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
CYP2C9 encodes a member of the cytochrome P450 superfamily of enzymes. Zusätzlich bieten wir Ihnen CYP2C9 Kits (22) und CYP2C9 Proteine (4) und viele weitere Produktgruppen zu diesem Protein an.
Showing 10 out of 58 products:
Human Polyclonal CYP2C9 Primary Antibody für Func, IHC (fro) - ABIN2473172
Gilhodes, Gurfinkel, Roll: Role of Ia muscle spindle afferents in post-contraction and post-vibration motor effect genesis. in Neuroscience letters 1992
Show all 4 Pubmed References
Human Monoclonal CYP2C9 Primary Antibody für WB - ABIN1882233
Yang, Cui, Hasi, Jia, Gong, Su: Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China. in Genetics and molecular research : GMR 2010
Show all 3 Pubmed References
SNP rs4918758 of CYP2C9 showed a suggestive association with decreased risk of coronary heart disease.
CYP2C9*31075AC genotype with combined alcohol and nevirapine usage indicated a risk for development of antiretroviral-associated hepatotoxicity
CYP2C9 polymorphisms showed no effect on PC doses. Similar findings were observed in the initiation phase of PC therapy. High complications rates under PC therapy were observed particularly at the beginning.
Genetic variants of CYP2C9/VKORC1 (zeige VKORC1 Antikörper) and age are significant determinants of the maintenance dose of warfarin in patients with atrial fibrillation/valve replacement.
CYP2C9*3 polymorphism genotype and allele frequency were not statistically different between the case and control Ankylosing Spondylitis groups (P>0.05). the efficacy of NSAID in treatment of AS and COX-2 (zeige COX2 Antikörper) gene -1290A/G and -1195G/A polymorphism were associated (all P<0.05), but it is not associated with CYP2C9 *3 polymorphism (all P>0.05).
polymorphisms c.98T>C in the UGT1A9 (zeige UGT1A9 Antikörper) and c.1075A>C in the CYP2C9 genes did not affect the pharmacokinetic profile of propofol
Possession of CYP2C9*2 and/or CYP2C9*3 allele variants is associated with lower time of international normalized ratio (INR (zeige INSR Antikörper)) in the therapeutic range (TTR (zeige TTR Antikörper)) values and warfarin dose variations in aortic valve replacement patients, the latter affected also by VKORC1 (zeige VKORC1 Antikörper) c.-1693G>A polymorphism
Three SNPs (CYP2C9 *2, *3 and VKORC1 (zeige VKORC1 Antikörper) c.-1639G > A) were genotyped by electrochemical detection using a sandwich-type format that included a 3' short thiol capture probe and a 5' ferrocene-labeled signal probe.
This study was aimed to describe the distribution of CYP2C9 and CYP2C19 (zeige CYP2C19 Antikörper) alleles and haplotypes in four Mestizo populations from Western Mexico. Frequencies ranged from 2.2-3.0% and 4.8-8.9% for CYP2C9*3 and CYP2C9*2 alleles, respectively, and 5.4-12.0% for CYP2C19 (zeige CYP2C19 Antikörper)*2, whereas the CYP2C19 (zeige CYP2C19 Antikörper)*3 allele was not found.
CYP2C9 IVS8-109 T carriers showed significantly higher dose-corrected phenoytoin blood concentrations and this allele was found in a higher frequency in epileptic patients with supratherapeutic phenytoin levels.
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by rifampin. The enzyme is known to metabolize many xenobiotics, including phenytoin, tolbutamide, ibuprofen and S-warfarin. Studies identifying individuals who are poor metabolizers of phenytoin and tolbutamide suggest that this gene is polymorphic. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24.
cytochrome P-450 S-mephenytoin 4-hydroxylase
, cytochrome P-450MP
, cytochrome P450 2C9
, cytochrome P450 PB-1
, flavoprotein-linked monooxygenase
, microsomal monooxygenase
, xenobiotic monooxygenase